Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.81)
# 1,801
Out of 4,902 analysts
80
Total ratings
45.76%
Success rate
7.38%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $22.55 | -2.44% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $11.65 | +28.81% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $8.28 | -3.38% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $18.28 | +173.52% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $134.11 | +1.41% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $3.88 | +312.37% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $6.47 | +858.27% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.67 | +618.56% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $9.14 | +129.76% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $21.97 | +396.13% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.48 | +440.54% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.79 | +258.42% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $5.77 | +1,633.10% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $5.19 | +15.61% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.06 | +586.27% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $104.17 | -77.92% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $26.71 | +34.78% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $22.55
Upside: -2.44%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $11.65
Upside: +28.81%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $8.28
Upside: -3.38%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $18.28
Upside: +173.52%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $134.11
Upside: +1.41%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $3.88
Upside: +312.37%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $6.47
Upside: +858.27%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.67
Upside: +618.56%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $9.14
Upside: +129.76%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $21.97
Upside: +396.13%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.48
Upside: +440.54%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $2.79
Upside: +258.42%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $5.77
Upside: +1,633.10%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $5.19
Upside: +15.61%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.06
Upside: +586.27%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $104.17
Upside: -77.92%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $26.71
Upside: +34.78%